Joel Habener

Joel Habener is a Professor of Medicine at Harvard Medical School.

Joel Habener

Habener worked with Svetlana Mojsov on elucidating the role of incretin hormones such as Glucagon-like peptide-1 (GLP-1) and Glucagon-like peptide-2 (GLP-2). Habener received credit for the work on hormones when Mosjov was not credited.[1] Habener was awarded the 2020 Warren Alpert Foundation Prize along with Daniel Drucker and Jens Juul Holst.[2] He was elected to the National Academy of Sciences in 2020.[3] In 2021 he was awarded the Canada Gairdner International Award.[4] In 2023, he received the VinFuture Prize.[5] In 2024, he was awarded the Princess of Asturias Awards for Technical and Scientific Research.[6] and also in 2024 the Tang Prize in the category of "Biopharmaceutical Science".[7]

References
  1. Molteni, Megan; Chen, Elaine (27 September 2023). "The Ozempic revolution is rooted in the work of Svetlana Mojsov, yet she's been edged out of the story". STAT. Retrieved 2023-10-09.
  2. "Prize Recipients | Warren Alpert Foundation Prize". warrenalpert.org.
  3. "2020 NAS Election". www.nasonline.org.
  4. Canada Gairdner International Award 2021
  5. Nhu, Quynh (21 December 2023). "Battery researchers win $3M Vietnamese awards". VnExpress.
  6. Princess of Asturias Awards 2024
  7. Tang Prize 2024


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.